The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
REGULATORY
MHLW to Continue to Suspend HPV Vaccine Recommendation
The Ministry of Health, Labor and Welfare (MHLW) will maintain the suspension of its active recommendation for cervical cancer vaccines after a follow-up survey found that 186 girls who experienced post-vaccination symptoms have not yet recovered. Two MHLW panels advised…
To read the full story
Related Article
- MSD Renews Call for Reinstating Govt’s HPV Vaccine Promotion after WHO Statement
January 15, 2016
- Active Promotion of HPV Vaccines Should Be Resumed: GSK
October 1, 2015
- Can’t Give Timeline for Active Recommendation for HPV Vaccines, Expert Discussions Eyed: Govt
September 8, 2015
- MHLW to Issue Notification with Survey Form on Adverse Reactions to HPV Vaccines
October 31, 2014
- MHLW to Reinforce Follow-Up Surveys on HPV Vaccine Recipients
September 1, 2014
- Ministry Joint Panel Says Evidence Linking HPV Vaccine Adjuvant with Side Effects Weak
February 27, 2014
- HPV Vaccine Injection Site Pain Possible Cause of Chronic Pain: MHLW Subcommittees
January 21, 2014
- Active Recommendation for HPV Vaccines Remains Suspended
December 26, 2013
- Health Ministry Subcommittees Agree to Continue Suspending Recommendation for HPV Vaccines
October 30, 2013
REGULATORY
- Japan to Cut Drug Prices by 0.86% in FY2026; Central Govt Savings Seen at 105 Billion Yen
December 25, 2025
- Japan Growth Strategy Council to Set Up Drug Discovery Working Group
December 25, 2025
- Japan Ministers Agree to Scrap “Spillover” Rule, Plan Wider CEA Price Cuts
December 25, 2025
- Takeda Plans January Rollout of Overseas Plasma-Derived Ig amid Suspension
December 25, 2025
- Japan Panel OKs Label Warning Update for Labor Inducers to Mention Epidural Births
December 25, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…